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Abstract
Introduction: The purpose of this study was to determine the primary patency rate of endovascular inter-
ventions in hemodialysis patients who had central venous stenosis or occlusion. 
Material and methods: Twenty-seven hemodialysis patients, who underwent endovascular intervention 
between January 2013 and January 2018 for central venous stenosis or total obstruction, were included in the 
study. Endovascular interventions consisted of percutaneous transluminal angioplasty (PTA) or stent implantation. 
Primary patency rate of endovascular intervention at the sixth and twelfth months were evaluated.
Results: Stent implantation and PTA were used in 5 patients and 22 patients, respectively. Fourteen patients 
had stenosis and 13 patients had occlusion. The total procedural success rate was 81%, 86% in stenosis and 
77% in occlusion. There was no procedure-related complication. The primary patency for PTA at 6 and 12 
months were 40% and 10%, respectively. For stent implantation, primary patency rate at 6 and 12 months 
was 70% and 30%, respectively. 
Conclusion: Endovascular interventions for central venous stenosis and occlusion are safe, with low rates of 
technical failure and they can be first-line treatment for central venous stenosis or occlusion in hemodialysis 
patients.
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Introduction
Central (superior vena cava, brachiocephalic, or 
subclavian) vein stenosis and occlusion are an important 
complication in hemodialysis patients. Central venous 
stenosis or occlusion usually occurs as a complication 
of central venous catheterization and significantly com-
plicates dialysis. Clinically, central venous stenosis or 
occlusion manifests as ipsilateral arm or neck swelling 
and failure of hemodialysis access. 
Surgical and endovascular treatments are available 
for the treatment of central venous stenosis or occlu-
sion. Surgical treatment is often difficult and may not al-
ways be successful. Surgical approaches require general 
anesthesia and have high surgical morbidity in patients 
with end-stage renal disease. However, percutaneous 
treatment for central venous stenosis is feasible and 
efficient. Surowiec et al. [1] showed that transvenous 
angioplasty was helpful for hemodialysis patients with 
central venous stenosis and helped maintain functional 
access in the affected limb. Endovascular treatment 
options include percutaneous transluminal angioplasty 
(PTA) or stent implantation. The optimal endovascular 
treatment remains unclear; the superiority of stent 
placement compared with PTA has not been fully 
established [1–3]. The National Kidney Foundation 
Disease Outcomes Quality Initiative guidelines have 
recommended angioplasty as initial treatment; stenting 
is indicated in case of central vein stenosis recurring 
within 3 months [4, 5].
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The aim of the study was to determine 6-month 
and 12-month primary patency of percutaneous bal-
loon angioplasty and stent implantation in hemodialysis 
patients who had central venous stenosis or occlusion. 
Material and methods
This study was a retrospective, single-center study 
based on collected data of endovascular interventions 
which were PTA or stent implantation for central ve-
nous stenosis or occlusion. Data were collected from 
the interventional radiology department database from 
January 2013 to January 2018. The study was approved 
by the ethics committee. Written informed consent was 
obtained from all the patients. 
PTA or stent implantation was performed in end-
stage renal failure patients on hemodialysis who had 
clinical signs of central venous stenosis or occlusion. 
All patients had a history of central hemodialysis cath-
eter placement. Clinical signs in these patients were 
prolonged post-hemodialysis hemorrhage, increased 
venous pressure, ipsilateral arm or neck swelling and 
decreased blood flow during dialysis sessions. Patients 
who had previous PTA or stent implantation and 
previous surgical treatment for the same lesion were 
excluded from the study. In all patients, the location and 
length of the stenosis or occlusion were evaluated by 
diagnostic venography before the intervention.
Endovascular interventions were started with ante-
grade puncture with an 18-G needle into the proximal 
stenotic/occlusive vein and a 7-French vascular sheath 
was inserted via this vein. Antegrade venous access 
through the common femoral vein was added to the 
procedure in difficult cases. A total dose of 3000 IU 
heparin was injected via the vascular sheath to prevent 
thrombus formation. The stenotic site was traversed 
using a 0.035-inch hydrophilic guidewire (Terumo, NJ, 
USA). For some hard lesions, different guidewires, 
such as stiff guidewire or 0.018-inch guidewire or mi-
crocatheter, were also used for passing the stenosis/ 
/occlusion. PTA or stent implantation was performed 
after traversing the lesion. Depending on the size of the 
vessels, PTAs were 1 mm larger (ranging from 10 to 
14 mm) than the normal size of the venous segment, 
and the length of the balloons ranged from 2 to 8 cm 
(Fig. 1). Stenting was performed if a residual stenosis of 
greater than 50% was present after PTA. Only bare self-
expanding metal stents (Wallstent, Boston Scientific, 
Natick, MA, USA) were used and the diameter of the 
stent was chosen nearly the same as the adjacent normal 
vein (Fig. 2). Stent diameters ranged from 10 to 14 mm, 
with length ranging from 4 to 6 cm. Post-dilatation with 
a balloon often was performed after stent deployment 
to improve  stent expansion. A final angiogram was 
performed to evaluate residual stenosis and technical 
failure was defined as inability to cross the stenotic or 
occlusive segment and residual stenosis > 30%.
The primary patency was defined as patency in 
the patent central vein without recurrent stenosis or 
occlusion. Assisted primary or secondary patency was 
defined as a patent central vein that underwent further 
intervention to improve patency.
Statistical analysis 
Statistical analyses were performed using Statistical 
Package for the Social Sciences (SPSS) 17.0 statistical 
software for Windows (SPSS Inc., Chicago, IL, USA). 
The chi-square test and Kaplan-Meier analysis were 
used to calculate primary patency of the PTA and stent 
implantation in the groups (Fig. 3). 
Figure 1. A 58-year-old patient with a history of 10-year hemodialysis. A — initial diagnostic venogram showed complete oc-
clusion of right subclavian vein; B — the lesion was crossed anterogradely using guide wire, and PTA was performed; C — post 
PTA venogram showed normal filling of right subclavian vein. During follow-up, the patient had not any recurrence at 12 months
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Results
Endovascular procedures were performed in 27 
hemodialysis patients with central venous stenosis or 
occlusion. There were 14 (52%) males and 13 (48%) 
females. The mean age of the patients was 62.2 ± 14 
years (range, 35−87 years). Stent implantation was 
used for 5 patients and PTA for 22 patients. Before 
endovascular treatment, 14 patients had stenosis and 
13 had occlusion. Only PTA was performed in 86% of 
14 patients with venous stenosis and 77% of 13 patients 
with occlusion, while other patients underwent stent 
angioplasty. The sites of central vein stenosis or occlu-
sion were the superior vena cava in 11 cases, brachio-
cephalic vein in 15 cases and the subclavian vein in 1 
case. Demographic characteristics of the patients are 
summarized in Table 1. The overall procedural success 
rate for PTA and stent implantation was 83%; 100% 
in stenosis and 70% and 100% in occlusion. After bal-























Figure 2. A 66-year-old patient with a history of 8-year hemodialysis. A — initial diagnostic venogram showed serious stenosis of 
superior vena cava. B, C — predilatation and stent implantation was performed. D — post procedure venogram showed normal 
filling of superior vena cava. At follow-up, restenosis was seen at 8 months
Figure 3. Kaplan-Meier graphs: a comparison of 12-month 
primary patency rates between PTA and stent implantation
Table 1. Demographic data and procedural details of patients
Mean age of patients 66 ± 14 years 
Sex (female) 13 (48%)





Superior vena cava 11 (40%)
Brachiocephalic vein 15 (55%)
Subclavian vein 1 (3%)
Mean length of the lesions
Stenosis 36.2 ± 6.2 mm
Occlusion 28.5 ± 4.3 mm
Endovascular therapy 
Percutaneous balloon angioplasty 22 (81%)
Stent implantation 5 (19%)
Size of balloons used
Superior vena cava (8 patient) 12*40 mm (x 4), 
12*60 mm (x 2), 
14*40 mm (x 2)
Brachiocephalic vein(13 patient) 12*40 mm (x 6), 
10*40 mm (x 3), 
10*60 mm (x 4)
Subclavian vein (1 patient) 8*40 mm (x 1)
Size of stents used
Superior vena cava (3 patient) 12*40 mm (x 2), 
14*40 mm (x 1)
Brachiocephalic vein (2 patient) 12*40 mm (x 2)
Balloons and stents are expressed as diameter * length in mm 
A B C D
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was detected in the control angiograms in 2 patients 
who had stenosis and 3 patients who had occlusion, 
which were considered as technical failure. The total 
success rate for all procedures was 81%. There were 
no procedure-related complications and all patients 
underwent hemodialysis after the initial procedure. 
The primary patency for PTA at 6 and 12 months 
was 40% and 10%, respectively. For stent implanta-
tion, primary patency at 6 and 12 months was 70% 
and 30%, respectively. The mean reintervention time 
was 7 months for PTA and 11 months for stent implan-
tation. The mean reintervention time was 11 months 
in patients with stenosis and 6 months in patients 
with occlusion. There was no statistically significant 
difference between balloon angioplasty and stent im-
plantation groups according to the chi-square test and 
Kaplan-Meier analysis (p > 0.05).
In the PTA group, 20 (91%) initial PTAs required 
secondary intervention during the 12-month follow-up 
period due to loss of primary patency. Secondary PTA 
was used in 18 patients and 2 patients underwent stent 
implantation. In the stent implantation group, 3 (70%) 
patients required secondary intervention and PTA was 
applied to these patients. Total reinterventions in both 
groups were required 23 (85%) patients during the 
12-month follow-up period, but only 8 patients were 
followed up 6 month after second intervention and 
secondary patency was seen 75% at 6 months. 
Discussion
The number of patients with chronic renal failure 
requiring hemodialysis is increasing and a smooth vascu-
lar structure is required for successful dialysis. Vascular 
complications are one of the main causes associated 
with an increase in morbidity and mortality in hemodi-
alysis patients. Central venous stenosis and occlusion 
are a major concern in patients receiving prolonged 
hemodialysis. There are various surgical approaches 
to management of central venous stenosis or occlusion 
such as interposition grafting to the internal jugular vein, 
and direct patch angioplasty of axillo-subclavian stenosis 
which include jugular venous turndown. The results of 
surgical reconstruction of the central veins are better 
than those of endovascular therapy with primary pa-
tency rates of 80% to 90% at one year [6]. However, 
these surgical approaches are difficult to perform in 
hemodialysis patients with numerous comorbidities. 
Central veins are generally obscured by the bony skel-
eton and these major surgeries often require clavicular 
division or sternotomy along with general anesthesia. 
Endovascular treatments are less invasive and therefore 
preferred over surgical treatment in many centers. 
Exceptionally, subclavian vein stenoses adjacent to the 
costoclavicular junction respond poorly to treatment 
with endovascular therapy because of extrinsic com-
pression at the thoracic outlet. The optimal treatment 
of access-related venous stenosis at this location must 
include a transaxillary first rib resection and mobilizing 
the subclavian vein to the jugular confluence [7]. En-
dovascular therapy is not usable only for benign central 
venous stenosis and occlusion but also for malignant 
processes. Also, surgical resection and reconstruction 
of the superior vena cava in selected patients with ma-
lignant mediastinal tumors may be very beneficial [8].
One of the negative consequences of endovascular 
treatment is acceleration of occlusion formation. Re-
current lesions after angioplasty have more aggressive 
neointimal hyperplasia than the primary lesion because 
the mechanism of angioplasty involves cracking and 
fissuring of the vessel intima which can increase neoin-
timal hyperplasia [9]. The endovascular therapy options 
include balloon angioplasty and stent implantation. 
Although, transluminal angioplasty is the preferred 
treatment for central venous stenosis or occlusion [4], 
optimal endovascular management strategy is unclear 
in many centers. 
In this study, the total procedural success rate was 
found to be 81%; it ranges between 70% and 90% in 
the literature [1, 2, 10–12]. The primary patency for 
PTA at 6 and 12 months was 40% and 10%, respec-
tively. For stent implantation, primary patency at 6 and 
12 months was 70% and 30%, respectively. Previous 
studies showed that primary patency rates for PTA 
ranged between 23% and 55% at 6 months and 12% 
and 50% at 12 months and primary patency rates 
for stent implantation ranged from 42% to 89% at 
6 months, and from 14% to 73% at 12 months [1–3, 
11, 13–16]. Our results were correlated with these 
studies. In our study, secondary or assisted primary 
patency rate was 75% during the 6-month follow-up. 
As we know, stent implantation has some late 
complications such as stent fracture and migration of 
the distal stent fragment to the inferior vena cava or 
stent compression distortion. In our cases, there were 
no stent-related late complications and all patients 
underwent hemodialysis after the initial procedure. 
In our study cohort, only bare self-expanding metal 
stents were used. The bare self-expanding metal stent 
(Wallstent) excels as a conduit, rarely fracturing or fail-
ing primarily through the main body of the stent. The 
stent maintains strength via both radial force and com-
pression resistance. Although the bare self-expanding 
metal stent has proven advantageous, there remain two 
critical shortcomings. First, the edges of the stent are 
weaker than the main body, making it prone to collapse. 
And he second is the lack of deployment accuracy and 
precision, making it prone to stent forshortening. In our 
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cases, there were no collapse and significant shortening 
of stent after procedure. New generation nitinol venous 
stents design is advantageous for improved precision 
and accuracy during deployment without significant 
stent forshortening. Studies comparing PTA and stent-
ing in central venous lesions reported that the patency 
rates in central lesions were equal at 12 months [2, 3]. 
Restenosis is common after PTA or stent implantation, 
therefore, cost effectiveness is now being questioned 
in many centers. Stent implantation in our country is 
3–4 times more expensive than PTA. So, we prefer PTA 
firstly in hemodialysis patients with initial stenosis and 
occlusion. However, in patients with residual stenosis 
greater than 50% after PTA, stent implantation was 
performed.
Mid-term primary patency rate of endovascular 
intervention and surgical treatment are similar in cen-
tral stenosis or occlusion, with a significant incidence 
of secondary interventions [17]. It would be beneficial 
to choose endovascular intervention as a first-line 
treatment because of its less invasiveness and cost-ef-
fectiveness. 
Our study has certain limitations. First, our sample 
size was small. It was necessary to collect data over a 
long time period to have a sufficient number of cases 
for statistical power. Additional limitations were retro-
spective nature of the study, availability of only limited 
width bare self-expanding metal stents and absence of 
surgically treated cases.
Conclusion
Although long-term patency rates of endovascular 
interventions in central venous stenosis and occlusion 
in hemodialysis patients are not satisfactory, because of 
less invasive nature and high technical success rate, it 
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